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Neuronal nicotinic acetylcholine receptors (nAChRs) are pentamers built from a variety of subunits. Some are homomeric assemblies of
 subunits, others heteromeric assemblies of and subunits which can adopt two stoichiometries (2:3 or 3:2). There is evidence
for thepresenceof heteromeric nAChRswith the two stoichiometries in theCNS, but it hasnot yet beenpossible to identify themat a given
synapse. The 2:3 receptors are highly sensitive to agonists, whereas the 3:2 stoichiometric variants, initially described as low
sensitivity receptors, are indeed activated by low and high concentrations of ACh. We have taken advantage of the discovery that two
compounds (NS9283 and Zn) potentiate selectively the 3:2nAChRs to establish (inmice of either sex) the presence of these variants at
the motoneuron-Renshaw cell (MN-RC) synapse. NS9283 prolonged the decay of the two-component EPSC mediated by heteromeric
nAChRs. NS9283 and Zn also prolonged spontaneous EPSCs involving heteromeric nAChRs, and one could rule out prolongations
resulting fromAChE inhibitionbyNS9283. These results establish thepresenceof 3:2nAChRsat theMN-RCsynapse.At the functional
level, we had previously explained the duality of the EPSC by assuming that high ACh concentrations in the synaptic cleft account for the
fast component and that spillover of ACh accounts for the slow component. The dual ACh sensitivity of 3:2 nAChRs now allows to
attribute to these receptors both components of the EPSC.
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Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are iono-
tropic receptors with a cationic selectivity, which makes them
excitatory. They are pentamers built either from subunits (homo-
meric nAChRs) or from  and  subunits (heteromeric nAChRs)
(Dani, 2015). Heteromeric nAChRs can associate multiple  and
 subunits and in addition, for a given set of and subunits, can
adopt two stoichiometries noted either 2:3 and 3:2 or A2B3
and A3B2 (Marotta et al., 2014). There is evidence for the pres-
ence in the CNS of the two stoichiometric variants of heteromeric
nAChRs (Marks et al., 1999, 2007; Shafaee et al., 1999; Gotti et al.,
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Significance Statement
Heteromeric nicotinic receptors assemble and subunits inpentameric structures,which canadopt two stoichiometries: 3:2
or 2:3. Both stoichiometric variants are present in the CNS, but they have never been located and characterized functionally at
the level of an identified synapse.Ourdata indicate that 3:2 receptors are present at the spinal cord synapses betweenmotoneu-
rons and Renshaw cells, where their dual mode of activation (by high concentrations of ACh for synaptic receptors, by low
concentrations of ACh for extrasynaptic receptors) likely accounts for the biphasic character of the synaptic current. More
generally, 3:2 nicotinic receptors appear unique by their capacity to operate both in the cleft of classical synapses and at
extrasynaptic locations.
The Journal of Neuroscience, May 23, 2018 • 38(21):4943–4956 • 4943
2007; DeDominicis et al., 2017). However, until now it has not
been possible to assess the presence of a given variant at a specific
synapse. We have attempted such a characterization in the spinal
cord, at the synapses between the motoneurons (MNs) and the Ren-
shaw cells (RCs), first characterized as cholinergic by Eccles et al.
(1954), and in which postsynaptic heteromeric nAChRs mediate
a biphasic EPSC, which decays with time constants in the 10 and
100 ms ranges (Lamotte d’Incamps and Ascher, 2008).
The various heteromeric nAChRs differ by a number of prop-
erties but in particular by their sensitivity to ACh. Considerable
progress has been made recently in characterizing these differ-
ences, and in particular to explain why the EC50 of the concen-
tration response relation (CRR) depends on the stoichiometric
variant examined. Differences in ACh sensitivity between the two
variants built from the same subunits were best described for
recombinant receptors associating4 and2 subunits (Zwart and
Vijverberg, 1998; Nelson et al., 2003; Zhou et al., 2003; Kuryatov
et al., 2005; Moroni et al., 2006, 2008; Zwart et al., 2006; Tapia et
al., 2007; Carbone et al., 2009). In (4)2(2)3 nAChRs, the ACh
CRR is well fit by a single sigmoid with an EC50 of a few M. In
(4)3(2)2 nAChRs, the ACh CRR was initially described as mono-
phasic with a high EC50, but more recent studies have shown that it is
biphasic with a high sensitivity (HS) region (EC50 1 M) and a
low sensitivity (LS) region (EC50100M) (Harpsøe et al., 2011;
Grupe et al., 2013; Eaton et al., 2014). Similar differences were
observed for stoichiometric variants of 22 and 24 nAChRs
(Wang et al., 2015). At the molecular level, these differences have
been shown to result from the absence or presence of an -
interface. In (4)2(2)3 nAChRs, ACh binds (with high affinity)
to the two - interfaces. In (4)3(2)2 nAChRs, ACh also binds
to the two - interfaces but only elicits a partial activation; the
full activation requires (low affinity) binding of ACh to the -
interface (Harpsøe et al., 2011; Mazzaferro et al., 2011, 2014;
Eaton et al., 2014), which is thus an ACh “accessory binding site”
(Wang et al., 2015). Recently, two compounds have been found
to bind to this site and to potentiate the activation of A3B2 recep-
tors by ACh: NS9283 (EC50 of a few M) (Timmermann et al.,
2012; Grupe et al., 2013; Olsen et al., 2013; Wang et al., 2015;
Mazzaferro et al., 2017; Wang and Lindstrom, 2017) and Zn (100
M) (Moroni et al., 2008; Mazzaferro et al., 2011).
We have applied these two compounds at the MN-RC synapse
and found that NS9283 potentiates both evoked and spontaneous
EPSCs (sEPSCs), whereas Zn potentiates sEPSCs. A caveat intro-
duced by the observation that NS9283 is an inhibitor of AChE
was lifted when we found that this effect plays a minor role at
concentrations of NS9283 up to 10 M. Thus, A3B2 nAChRs are
present at the MN-RC synapse, and because of their dual ACh
sensitivity can mediate both components of the EPSCs: the fast
component involves binding of ACh to the three interfaces of
synaptic cleft receptors, whereas the slow component involves
binding of ACh to the - interfaces of extrasynaptic receptors.
Materials andMethods
All experiments were performed in accordance with relevant guidelines
and regulations at Universite´ Paris Descartes (ethical committee autho-
rization CEEA34.BLDI.068.12).
Animals and slice preparation.The mice used (of either sex) were either
wild-type (WT) C57BL/6J mice (Janvier) or knock-out lines for the 2
nAChR subunits: 2
/ (Picciotto et al., 1995) or 7
/ 2
/ (Somm et
al., 2014) obtained by crossing2
/mice with7
/mice (Orr-Urtreger
et al., 1997). All mutants were bred as homozygous; confirmation of the
genotype of the mice was made whenever necessary with the appropriate
PCR from small samples collected at P5.
The mice (P5-P10) were anesthetized with an intraperitoneal injection
of 0.1– 0.2 ml xylazine (0.25 mg/ml) and ketamine (3 mg/ml). The dis-
section and the slicing were performed as described previously (Lamotte
d’Incamps et al., 2012). Slices were then transferred into ACSF containing
the following (in mM): NaCl 130, KCl 2.5, CaCl2 2, MgCl2 1, NaH2PO4 1.0,
NaHCO3 26, glucose 25, Na-ascorbate 0.4, Na-pyruvate 2, bubbled with
95% O2 and 5% CO2, pH 7.4. For the Zn experiments, NaH2PO4 and
NaHCO3 were replaced by HEPES (10 mM) and NaCl concentration was
raised to 145 mM. After a 30 min incubation in ACSF at 34°C, slices were
maintained at room temperature (18°C–24°C).
Biochemistry. Recombinant mouse AChE (mAChE) was a generous
gift from Pr. Palmer Taylor (University of California–San Diego). Stock
solutions of NS9283 were prepared as 20 mM in 1 M HCl, and further
dilutions were prepared in HEPES buffer (0.1 M; pH 7.4). Reversible
inhibition of mAChE by compound NS9283 was measured in a medium
(0.1 M sodium phosphate buffer, pH 7.4), which contains substrate
acetylthiocholine iodide (ATC) ( Sigma-Aldrich) (range 0.1–1 mM) and
reagent 5,5-dithiobis(2-nitrobenzoic acid) (0.3 mM) according to the
Ellman method (Ellman et al., 1961) at 415 nm and 25°C, using a Bio-Rad
microplate reader. Additionally, control enzyme activity without the in-
hibitor was measured. There was no spontaneous hydrolysis of ATC with
NS9283, and no solvent interference on AChE activity in the tested range
of NS9283 (0.2–9 M). Higher concentrations of NS9283 could not be
used due to solvent inhibition. The inhibition constants were evaluated
from the effect of ATC concentration(s) on the degree of inhibition by
NS9283 (at concentration I) according to the equation: v  Vm 
s/(Km(1 I/Ki) s), which describes the noncompetitive inhibition and
from which the dissociation constant Ki was calculated (Cornish-
Bowden, 2012). The value of theKm in the absence of NS9283 was 0.10
0.01 mM, similar to the values obtained on the same enzyme by Sˇinko et
al. (2010).
Electrophysiology. HEKA EPC-9 or Molecular Devices Axopatch 200B
amplifiers were used for data acquisition. Whole-cell recordings were
filtered at 3 kHz and digitized at 10 kHz. Series resistance (range 8 –30
Mohms) was corrected (60%) in most recordings of sEPSCs and in all the
recordings of EPSCs evoked by ventral root (VR) stimulation.
The recording chamber was continuously perfused with ACSF at a rate
of1 ml/min. RCs were first identified by their characteristic response to
VR stimulation and voltage-clamped in the whole-cell configuration.
Patch pipettes had an initial open-tip resistance of 3.5 to 6 MOhms. The
internal solution contained the following (in mM): Cs-gluconate 125,
spermine 10, QX-314 Cl 5, HEPES 10, EGTA or BAPTA 10, CaCl2 1,
Mg-ATP 4, and Na2GTP 0.4. The pH was adjusted to 7.3 with CsOH, and
the osmolarity to 285–295 mOsm. Membrane potentials were corrected
for the liquid junction potential (Vj15 mV). Except when indicated
otherwise, the recordings illustrated were obtained at60 mV. The glu-
tamatergic components of the EPSCs were suppressed by adding NBQX
(2 M) to block AMPARs and D-APV (50 M) to block NMDARs. 7
nAChRs were blocked by methyl-lyc-aconitine (10 nM). GABAergic and
glycinergic currents were blocked by SR 95531 (gabazine, 3 M) and
strychnine (1M). Stock solutions of NS9283 were prepared at 20 mM in
DMSO.NBQX,D-APV,gabazine,NS9283(3-[3-(3-pyridyl)-1,2,4-oxadiazol-
5-yl]benzonitrile), and sazetidine-A (saz-A) (6-(5-(((S)-azetidin-2-yl)
methoxy)pyridine-3-yl)hex-5-yn-1-ol) were purchased from Tocris
Bioscience and Ascent, except for an initial gift of NS9283 from Dr
Dan Peters. Galantamine hydrobromide was from Abcam, and QX-
314 chloride was from Alomone Labs. All other chemicals were from
Sigma-Aldrich.
Analysis of EPSCs.Evoked EPSCs (eEPSCs) (elicited by stimulation of the
VR) and sEPSCs were analyzed with Neuromatic (www.Thinkrandom.
com) as described previously (Lamotte d’Incamps et al., 2012). We ana-
lyzed the eEPSCs evoked by single pulses (1p) and by 5 pulse trains (5p,
frequency 100 Hz). Stimulations (either 1p or 5p) were repeated at 10 s
intervals. In all figures, eEPSCs are shown as averaged records of 10
responses, whereas sEPSCs are shown as average of as many events could
be collected during the experiment. The decay time constants were mea-
sured by fitting a double exponential after the peak of the last EPSC from
the response in the RC. The two components of the fit were each de-
scribed by their amplitude and their time constant: 	a1, 1
 is the fast
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component of the decay and	a2, 2
 the slow one. a1
1p, 1
1p, a2
1p, and 2
1p
are the values calculated for the responses to a single pulse, a1
5p, 1
5p, a2
5p,
and 2
5p those calculated for the decay from the peak of the response to the
fifth pulse of a train. The weighted decay time was calculated as w (a1
 1 a2 2)/(a1 a2). The double exponential fit assumes that both
components reach their peak at the same time, but, as we discussed
previously, the slow component has probably a slower rise than the fast
one (Lamotte d’Incamps et al., 2012). In such a case, the rise of	a2, 2

will overlap with the decay of	a1, 1
, and the fit will overestimate the
value of 1. Moreover, if there is a change in the second component, the
estimate of the parameters of the first component will suggest a change
even if there is not actually one. This difficulty, which could not be
resolved as we have not been able to eliminate selectively the fast com-
ponent to evaluate the rise of the second, complicates the interpretation
of the effects of NS9283 on the first component of the EPSC. In the
experiment illustrated in Figure 1A, the early decay of the 1p-EPSCs was
clearly not affected by NS9283 and yet the double exponential fit sug-
gested a reduction of 1 from 10.2 to 8.3 ms (see Fig. 1A). The peak of the
1p-EPSC was slightly reduced (from 462 to 419 pA), but the calculated
value of a1 was reduced from 377 to 300 pA. In Figure 1B, the peak of the
5p-EPSC increased from 569 pA to 579 pA and the early decay was
unchanged, but the values from the fit suggested a decrease of a1
5p from
412 to 260 pA and of 1
5p from 13.8 to 10.9 ms. Overall, our quantitative
analysis of the second component was robust but the quantification of
the fast component remained approximate.
For sEPSCs, the fit was only made on averaged records. The detection
threshold was set between7 and12 pA depending on the background
noise level, which was increased by some of the compounds having anti-
AChE effects (see Results). The relatively high value of the threshold
resulted in a slight overestimate of the mean amplitude, due to the ab-
sence of correction for the missed small events. In our early analysis of the
decay of spontaneous and miniature EPSCs, we fit the decay with single
exponentials because we were not able to detect a slow component (this
observation was one of our reason to suggest that the slow component of
the eEPSC reflects activation by spillover of extrasynaptic receptors). The
fact that under NS9283 a slow component appears in sEPSCs (see Fig.
1C) suggested the possibility that a small slow component could be already
present in sEPSCs in control conditions; indeed, when we reevaluated our
data using longer time bases than that used in our early analysis, we could
actually identify a slow component. However, this component was small;
and in many cases in which an overall slowing could be well documented,
it was difficult to separate the contributions to the slowing of changes of
a2 and changes of 2 (see Fig. 6).
The changes in the variance of the holding current were measured with
Neuromatic on records 500 ms long. The “apparent elementary current,”
iel, was calculated as the ratio between the change of the holding current
over the change of variance.
Experimental design and statistical analysis. Electrophysiological re-
cordings were obtained from spinal cord slices of young (P6-P10) mice of
either sex. One cell per slice was recorded to avoid residual effects of the
compounds used. Experiments were repeated at least three times in slices
obtained from several animals. One-sample t tests, Wilcoxon-Mann-
Whitney, paired t tests, or Welch tests in the case of unpaired data were
used to assess the difference between two samples (the tests were unilat-
eral unless noted). Values are given as mean SD.
Results
NS9283 amplifies the slow component of eEPSCs and
prolongs both evoked and sEPSCs
Our previous analysis of the synaptic currents mediated by het-
eromeric nAChRs at the MN-RC synapse had led us to propose
that LS receptors are responsible for the fast component of the
eEPSC, whereas HS receptors account for the slow component
(Lamotte d’Incamps et al., 2012). However, the data on the ACh
sensitivity of the various stoichiometric variants of nAChRs left
open whether the HS receptors mediating the slow component
are A2B3 receptors or A3B2 receptors operating at the foot of
their CRR (Lamotte d’Incamps and Ascher, 2014). The discovery
that NS9283 selectively potentiates A3B2 receptors offered a tool
to answer this question because it predicted that NS9283 would
potentiate the slow component if this component involves A3B2
receptors.
Timmermann et al. (2012) first established that NS9283 selec-
tively potentiates the stoichiometric variants of 42 recombinant
receptors expressing a high 4/2 ratio and therefore consisting
mostly of A3B2. Grupe et al. (2013) analyzed the effects of NS9283
on the ACh CRR of these receptors. In control conditions, the
ACh CRR has a first limb with an EC50 close to 1M and a second
larger limb with an EC50 of 100 M, as first described by
Harpsøe et al. (2011). Under a saturating concentration of
NS9283 (10 M), the ACh CRR becomes monophasic with an
EC50 close to 1 M.
To analyze the effects of NS9283 on the eEPSCs, we applied it
at 1, 3, and 10 M (the peculiar effects of higher concentrations
will be described in a separate section). We observed that the slow
component of the EPSC was amplified and its decay slowed. This
is illustrated for NS9283 at 10M in Figure 1A, B both for 1p and
5p stimulations. The analysis of the time constants (1 and 2) and
the amplitudes (a1 and a2) of the two components of the decay
showed that the time constant of the fast component (1) was
slightly shortened by NS9283, whereas the time constant of the
slow component (2) was markedly increased. Figure 1D illus-
trates the results of multiple experiments in the case of 1p-EPSCs.
The most visible change was the increase of 2, which in control
had a mean value of 145  25 ms (n  13) and increased by a
factor of 1.6  0.2 (n  6, t(5)  5.8138, p  0.0011, paired t
test) with NS9283 1 M, 2.1  0.4 (n  5, t(4)  6.7618, p 
0.0012) for NS9283 3 M and 2.1 0.6 (n 10, t(9)6.5197,
p 0.00005) for NS9283 10 M. In parallel, the amplitude of the
slow component (a2) increased. Because the values of the ampli-
tudes are very variable across experiments and, contrary to the
time constants, depend on the intensity of the stimulation of the
VR, we used the ratio of the value under NS9283 over the control
value in a given experiment to represent the increase of a2. The
mean control value of a2 was 43.3 24.9 pA (n 13). It increased
by a factor of 1.45 0.72 (n 6, t(5)1.7134, not significant,
p 0.074) with NS9283 1M, 2.1 0.6 (n 5, t(4)11.6216,
p  0.00016) for NS9283 3 M and 2.60  0.86 (n  10, t(9) 
3.9035, p 0.0018) for NS9283 10 M. Both a1 and 1 showed
a significant decrease for NS9283 10 M: a1 was reduced by 41%
from 318 96 pA down to 188 63 pA (n 10, t(9)10.4010,
p  1.39e6) and 1 from 11.1  1.3 ms down to 7.7  1.2 ms
(t(9) 5.3215, p 0.00024). The weighted time constants in-
creased at all three concentrations. With NS9283 10 M, the
weighted time constant for the 1p EPSC (w
1p) rose from 31.0 
8.2 ms (n 13) to 136.8 60.6 ms (n 10, t(9)5.9851, p
0.00010, paired t test with the corresponding controls) and the
weighted time constant for the 5p-EPSC (w
5p) rose from 64.6 
21.2 ms to 194.2 65.5 ms (n 8, t(7)7.2478, p 0.00009).
As discussed in Materials and Methods, the reductions of a1 and
1 are likely to be largely artifactual and due to the fact that we
could not correct for the fact that the slow component rises
slowly. NS9283 at concentrations of 1–10M did not significantly
affect the peak of the EPSC evoked by VR stimulation when tested
shortly after the drug application (10 min). A decrease of the EPSC
often occurred on a longer time scale but was also observed in the
absence of the drug, and likely to be linked with a presynaptic
fatigue. Thus, the major effect of NS9283 on the eEPSC appears to
be an increase of the slow component.
The fact that in the case of the eEPSCs NS9283 acts mainly on
the slow component led us to examine its effects on the sEPSCs.
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In our initial study of the nicotinic EPSCs mediated by hetero-
meric receptors in the RC (Lamotte d’Incamps et al., 2012), we
had fitted the decay of the sEPSCs by a single exponential with a
time constant close to that of the fast component of the fast eEPSC.
We had not seen a slow component but suspected its presence (Lam-
otte d’Incamps and Ascher, 2014) and indeed could detect it when
we used a longer time base (500 ms) than in our initial study and
forced a two-exponential fit on the decay of the averaged records
(Fig. 1C). The sEPSCs were compared in control conditions and
in NS9283 (10M). After addition of NS9283 10M, the decay of
the sEPSCs was slowed, as illustrated in Figure 1C. The weighted
time constant (w) increased from 15.2  4.9 ms in control to
26.5 9.9 ms (n 7, t(6)4.7813, p 0.0015). There were no
significant changes in the values of the amplitudes of the two
components (a1 went from 12.3 5.5 to 16.4 10.0 pA; n 7,
t(6)0.6314, p 0.28, and a2 went from 3.5 3.0 to 4.8 1.4
pA; n 7, t(6)0.7062, p 0.25, bilateral paired t tests). The
prolongation of the decay w involved both a slowing of the decay
of the first component (from 1 7.4 2.7 ms in control to 1
9.1 1.7 ms in presence of NS9283 10M; n 7, t(6)2.4648,
p  0.024) and an increase of 2 (from 53.8  37.7 ms up to
86.6 43.6 ms; n 7, t(6)2.7115, p 0.018).
The fact that NS9283 potentiates eEPSCs and sEPSCs strongly
suggests that A3B2 nAChRs are present at the MN-RC synapse.
BA C
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Figure1. NS9283potentiates andprolongs the slowcomponentof theMN-RCnicotinic eEPSC (A,B) andprolongs the sEPSCs (C). TheeEPSCswereelicitedbya stimulationof theVRwithonepulse
(1p, A) or five pulses (5p, 100 Hz, B). The decay was fitted by two exponentials, which defined four parameters: the amplitudes (a1, a2) and the decay time constants (1, 2) of the fast and slow
components. Theweighted time constant w combined these four values. A, Effect of NS9283 (10M) on a 1p eEPSC. CTL: a1 377 pA, a2 62 pA, 1 10.2ms, 2 129ms, w 27ms. NS9283: a1 300 pA,
a2 98 pA, 1 8.3 ms, 2 222 ms, w 60.9 ms. B, Effect of NS9283 (10M) on a 5p eEPSC (same cell as in A). CTL: a1 412 pA, a2 132 pA, 1 13.8 ms, 2 144 ms, w 45.4 ms. NS9283: a1 260 pA, a2 291
pA, 1 10.9 ms, 2 274ms, w 150ms. C, Effect of NS9283 (10M) on sEPSCs (same cell as in A, B). CTL average of 54 events, NS9283 average of 245 events. CTL: a119.7 pA, a21.0 pA, 1 9.2
ms, 2 51.2 ms, w 11.2ms. NS9283: a116.4 pA, a24.5 pA, 1 8.8 ms, 2 76.4 ms, w 23.3ms.D, Effects of three concentrations of NS9283 (1, 3, 10M) on the values of 2, a2, 1, and w for
1p eEPSCs. The values of the three time constants, which do not vary significantly as a function of the intensity of the VR stimulation, were plotted directly for each NS9283 concentration. For a2,
however, the value depends on the intensity of stimulation, which changes the number of axons excited, and this leads to the variability illustrated in the left part of the graph for the control value
(Ctrl). To evaluate the effects of NS9283, we plotted the value of the ratio of the amplitude measured in NS9283 over that measured in control (right ordinate scale). For 1, the values were those
measured fromthedouble exponential fit assuming that both components start at time0, but, as discussed inMaterials andMethods, this assumption leads to anapparent decrease,whichdisagrees
with the observation (A, B) that the decay of the early component of the EPSC is not changed by NS9283.
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The observation that NS9283 potentiates the slow components of
the synaptic currents supports the hypothesis that the HS recep-
tors are mostly A3B2 receptors operating at the foot of their
biphasic CRR.
NS9283 potentiates the currents induced by nicotinic agonists
The effects of NS9283 on the EPSCs strongly suggest the presence
of A3B2 nAChRs on the RC but do not exclude the simultaneous
presence of A2B3 receptors. To try to identify these receptors, we
made use of the observations indicating that many nAChR ago-
nists affect differentially the two stoichiometric variants so that
the responses they elicit differ in the ratio of the currents due to
A3B2 and A2B3 nAChRs. Because the potentiation by NS9283
only affects A3B2 receptors, it should be larger for agonists pref-
erentially activating A3B2 receptors than for those preferentially
activating A2B3 receptors. To test this hypothesis, we selected
four agonists: carbachol, nicotine, cytosine, and saz-A. Carbachol
was selected as an analog of ACh because of the observation (dis-
cussed in a later section) that NS9283 is an inhibitor of AChE. The
other three agonists (all insensitive to AChE) were selected be-
cause, at least in the case of 42 nAChRs, they act in different
proportions on the A2B3 and A3B2 nAChRs: nicotine acts on
both A3B2 and A2B3 nAChRs, cytisine has no agonist effect on
A2B3 nAChRs, and saz-A has more marked effects on A2B3 than
on A3B2 nAChRs.
Fast application of agonists was difficult in our experimental
conditions as the cells recorded from are situated rather deep in
the slices (at least 50 –100 m from the surface). We therefore
selected to bath apply the agonists and minimize desensitization
by using low concentrations. These “low” concentrations were
defined as lower or close to the EC50 values of the high-affinity
- interfaces deduced from the CRRs of A2B3 nAChRs and
from the foot of the biphasic CRRs of A3B2 nAChRs. Thus, we
could assume that most of the - interfaces were not occupied
by the agonist and accessible to NS9283. The low concentrations
of agonists induced inward currents that were steady for over a
few minutes. The stability of these currents does not indicate that
the receptors were not partly desensitized (Pidoplichko et al.,
1997; Paradiso and Steinbach, 2003) and indeed the agonists in-
duced a long-lasting depression of the EPSCs that was likely due
to desensitization, as described below. The stability only indi-
cated that a steady state was reached in the window defined by the
intersection of activation and desensitization relationships (Pi-
doplichko et al., 1997; Lester, 2004; Benallegue et al., 2013; Cam-
pling et al., 2013; Grupe et al., 2013).
Carbachol was applied at 2, 5, and 10 M. The EC50 of carba-
chol for 42 nAChRs was measured as 17 M by Eaton et al.
(2003) in experiments in which the EC50 for the HS limb of the
(4)2(2)3 ACh CRR was 1.7 M. At 2 M, carbachol induced
currents of a few 10s of pA (43.5 11.7 pA, n 6) and at 10 M
currents of a few 100 pA (241.0 65.3 pA, n 5; Fig. 2A,E). At
higher concentrations, the peak currents could reach several nA
but could not be clamped adequately and were always decreasing
rapidly. NS9283 (10 M) potentiated the currents induced by
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Figure 2. NS9283 potentiates the currents induced by the exogenous application of nicotinic agonists. Agonists were applied until the response reached steady state before adding NS9283
(10M) for10min. A, Carbachol 5M. B, Nicotine 0.2M. C, Cytisine 10 nM. D, saz-A 2 nM. E, Summary of the effects obtained in multiple experiments with various concentrations of agonists:
carbachol (2, 5, and 10M), nicotine (0.2 and 1M), cytisine (10 nM), and saz-A (2 nM). F, Mean values of the potentiation induced by NS9283 on the responses to the four agonists. Carbachol 2M:
2.1 0.3 (n 4). Nicotine 0.2M: 2.0 0.1 (n 3). Cytisine 10 nM: 3.3 1.0 (n 4). saz-A 2 nM: 4.0 4.0 (n 9).
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carbachol at 2 and 10 M. The mean potentiation was 2.1 0.3
(n 4, p 0.014, t(3) 8.0617, p 0.0020) for carbachol 2 M
(Fig. 2F) and 1.57 0.09 (n 4, t(3) 13.0481, p 0.00049) for
carbachol 10 M.
Nicotine was applied at 0.2 and 1 M, two values in the range
of the EC50 values measured in A2B3 recombinant nAChRs
containing 2 subunits (Nelson et al., 2003; Moroni et al., 2006;
Anderson et al., 2009; Campling et al., 2013), and lower than the
EC50 values for the main (LS) limb of A3B2 nAChRs measured by
the same authors. Nicotine at 0.2 M induced a current of
123.3  33.5 pA (n  3) and at 1 M a current of 215  93 pA
(n  5). NS9283 (10 M) potentiated the nicotine induced cur-
rent by 2.0 0.1-fold at 0.2M (n 3) and by 1.6-fold (n 1) at
1 M (Fig. 2B,E,F).
Cytisine was applied at concentrations ranging from 10 nM to
1 M. Cytisine has no agonist effect on 42 A2B3 receptors and
is a partial agonist of 42 A3B2 receptors (Papke and Heine-
mann, 1994; Houlihan et al., 2001; Eaton et al., 2003; Nelson et
al., 2003; Moroni et al., 2006; Carbone et al., 2009; Mazzaferro et
al., 2011; Campling et al., 2013; Marotta et al., 2014). Most studies
have described the activation of A3B2 receptors by a single sigmoid
with an EC50 between 1 and 16M (Eaton et al., 2003; Nelson et al.,
2003; Moroni et al., 2006; Carbone et al., 2009; Mazzaferro et al.,
2011; Campling et al., 2013; Marotta et al., 2014). However,
Papke and Heinemann (1994), in their pioneering study of the
effects of cytisine on 42 receptors which were likely A3B2 re-
ceptors, noted that the CRR had two components: with a first
plateau at concentrations of 100 nM and a second plateau at
concentrations
30 M (Houlihan et al., 2001). By analogy with
the CRR for ACh and nicotine on A3B2 nAChRs, these observa-
tions suggested that the action of cytisine on (4)3(2)2 nAChRs
involves both the - and the - interfaces, that the EC50 value
in theM range measured by most authors corresponds to that of
the LS limb of the CRR, and that the EC50 of the HS limb is in the
range of 10 nM. The currents induced by cytisine at 10 nM were
29.5 6.0 pA (n 4). The relatively small size of these currents
is in agreement with the claim that cytisine is a partial agonist.
NS9283 potentiated the responses to 10 nM cytisine by a factor of
3.3 1.0 (n 4, t(3) 4.7527, p 0.0089; Fig. 2C,E,F). Higher
concentrations of cytisine (1M) induced larger currents (145
69 pA, n  7), but these currents were not stationary and de-
creased during the application. NS9283 (10 M) was applied in
three experiments and induced a transient increase of a few 10s of
pA on the falling limb of the response.
saz-A was applied at concentrations of 2–50 nM. saz-A binds
exclusively to the - interfaces of 42 nAChRs. It is a full
agonist on 42 A2B3 receptors, and it is a partial agonist with
low efficacy (0.05% to 19%) on42 A3B2 receptors (Zwart et al.,
2008; Carbone et al., 2009; Mazzaferro et al., 2011; Eaton et al.,
2014; Indurthi et al., 2016). The reported EC50 values for the
activation of A2B3 and A3B242 nAChRs in expression systems
range from a few nM to 23 nM (Zwart et al., 2008; Carbone et al.,
2009; Mazzaferro et al., 2011; Eaton et al., 2014; Wang et al., 2015;
Indurthi et al., 2016). At a concentration of 2 nM, saz-A induced
inward currents of 35.6 21.0 pA (n 9). These currents were
potentiated by NS9283 (10M) and reached 90.1 35.5 pA (n
9) (Fig. 2D–F). Higher concentrations of saz-A induced rather
large currents: 171 136 pA (n 4) at 5 nM and 433 211 pA
(n 5) at 50 nM. In 3 of 5 cases, the responses to saz-A 50 nM were
not stationary and decreased with time, suggesting that desensi-
tization was progressively overcoming activation. In the other 2
cases, the current was stationary. The responses to saz-A 50 nM
were not potentiated by NS9283: the mean current value was
583 68 pA for saz-A and 595 81 pA for saz-ANS9283 (n
3). The absence of potentiation for “high” concentrations of
saz-A (50 nM) is likely explained by the fact that NS9283 shifts to
the left both the activation CRR and the desensitization CRR as
seen with ACh (Grupe et al., 2013), which means that the highest
agonist concentrations that initially induced a steady-state cur-
rent are now out of the range defining the “window currents.”
Our choice of the four agonists on which we analyzed the
steady-state effects of NS9283 was guided by the hope that, be-
cause these agonists do not activate in the same proportions A3B2
and A2B3 nAChRs, differences in the degree of potentiation by
NS9283 could reveal the presence of A2B3 receptors. This hope
was not fulfilled because the maximal potentiations were of sim-
ilar magnitude for the four agonists tested (carbachol, nicotine,
cytisine, saz-A) (Fig. 2F) and the weak trend suggesting a larger
effect in the case of saz-A is not consistent with our hypothesis: if
both A3B2 and A2B3 are present, the response to saz-A should be
dominated by that of A2B3 variants and thus should be less po-
tentiated by NS9283 than responses involving a comparable ac-
tivation of the two isoforms, or a preferential activation of A3B2.
The activation of A2B3 nAChRs by saz-A may be masked by a
preferential desensitization of these receptors (Campling et al.,
2013; Eaton et al., 2014). An alternative explanation of the results
is that there are actually very few A2B3 nAChRs in the RCs.
Carbachol, nicotine, and cytisine all reduced the amplitude of
the EPSCs. A reduction to	50% of the control was observed for
carbachol 5M (44 8%, n 5, t(4)14,8834, p 0.000059),
nicotine 1 M (46  13%, n  5, t(4) 9.6988, p  0.00032),
and cytisine 0.1 M (37  27%, n  4, t(3)  4.6806, p 
0.0092). After washing out the agonist, we observed a nearly com-
plete recovery of the EPSC in a few cases in which the agonist had
been applied at a low concentration and for	10 min. For longer
applications or for “high” concentrations (nicotine 10 M, cy-
tisine 1 M), the EPSC amplitude did not recover, which may
indicate that the receptors had entered a long desensitized state
(Pidoplichko et al., 1997; Paradiso and Steinbach, 2003). One
cannot exclude that part of the depression involves presynaptic
effects (McGehee et al., 1995). saz-A 2 nM reduced the amplitude
of the EPSC to 83  12% of its control value (n  10, t(9) 
4.6724, p  0.00058), with no significant effect on the decay
time constants (control w 50.7 33.8 ms, saz-A w 58.5
46.8 ms, n 8, t(7) 0.931, p 0.38). This is consistent with
the observation that, in the nM concentration range, saz-A pro-
duces little desensitization of (4)3(2)2 nAChRs (Eaton et al.,
2014). saz-A 50 nM reduced the EPSCs to 47 20% of its control
value (n 5, t(4)6.0809, p 0.0019) and after washing out
saz-A the reduction persisted despite the recovery of the saz-A
induced current.
The fact that NS9283 potentiates the currents induced by ACh
agonists not hydrolyzed by ACh and known to activate A3B2
nAChRs reinforces the conclusion that these receptors are pres-
ent at the MN-RC synapse. The similarity between the effects of
NS9283 on the currents induced by agonists activating in differ-
ent proportions A3B2 or A2B3 nAChRs suggests that, if A2B3
receptors are present at the synapse, they are not abundant.
NS9283 is a noncompetitive inhibitor of AChE
Although the prolongation by NS9283 of the heteromeric nicotinic
EPSC was that expected from a potentiation of A3B2 nAChRs, it also
resembled the prolongation of the EPSC induced by the AChE
inhibitor neostigmine (Lamotte d’Incamps et al., 2012). We thus
wondered whether NS9283 had any effect on AChE and assayed
the effect of NS9283 on the catalytic activity of purified mouse
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recombinant AChE using the Ellman method (see Materials and
Methods). The results showed that NS9283 is indeed an AChE
inhibitor (Fig. 3). The reduction of the AChE activity increased
with the concentration of NS9283, but theKm of the concentration-
activity relation of AChE (0.10 0.01 mM) was unchanged, indi-
cating a noncompetitive inhibition. The Ki was evaluated (see
Materials and Methods) as 11.2 M.
The observation that NS9283 has some anti-AChE effects
raised the possibility that some of the prolongation of the EPSC
decay by NS9283 could result from AChE inhibition, even if such
an inhibition cannot explain that NS9283 potentiates the re-
sponses to agonists not hydrolyzed by AChE (carbachol, nicotine,
cytisine, saz-A). To evaluate this possibility, we compared in de-
tail the effects of NS9283 and those of neostigmine, which we had
used in our previous study (Lamotte d’Incamps et al., 2012).
Because the concentration of NS9283 used in most of our exper-
iments (10M) was close to the Ki measured biochemically (11.2
M), we initially selected a concentration of neostigmine close to
the Ki of 7 nM measured in biochemical experiments by Santillo
and Liu (2015). At this concentration, no effect on the EPSCs was
detected. An effect was detected for neostigmine 30 and 50 nM
(Fig. 4). It developed slowly and did not show a clear plateau over
a period of 30 min. We measured it at a time between 20 and 30
min after the beginning of the application. For 30 nM, the effect
was most marked for 2
5p, which increased by50% (1.56 0.29,
n  3, t(2)  3.3289, p  0.040). At 50 nM, there was a more
marked prolongation, by a factor of 4.70  2.54 (n  7, t(6) 
8.8115, p  5.9e5) for 2
1p and 5.24  2.82 (n  7, t(6) 
7.6157, p  0.00013) for 2
5p (Fig. 4D1). In contrast, neostig-
mine had very limited effects on a2 (Fig. 4D2): at 30 nM, there was
no significant change in a2
1p and a2
5p; at 50 nM, a2
1p was actually
reduced by a factor of 0.76  0.24 (n  7; t(6)  2.6236, p 
0.0197), whereas no change could be detected in a2
5p. Over longer
applications, a2 tended to decrease, possibly due to desensitiza-
tion of the receptors by ambient ACh (Lamotte d’Incamps et al.,
2012).
The very slow development of the effect of neostigmine at nM
concentrations was likely due to the low rate of diffusion of the
compound in the slice. To confirm this point, we tested the effect
of an AChE inhibitor with a lower affinity, galantamine, for
which the Ki has been evaluated as 227 nM (Santillo and Liu,
2015). Galantamine had no effect at a concentration of 100 nM. At
1 M, it mimicked the effects of neostigmine: the mean value of
the time constant of the slow decay 2
1p increased by a factor of
2.6  1.6 (n  5, t(4)  2.6134, p  0.030), whereas a2
1p was
reduced by a factor of 0.62  0.33 (n  5, t(4)  2.517, p 
0.033). However, the effect developed in 10 –15 min after the
drug reached the slice, a rate comparable with that observed with
NS9283 and much faster than that observed with neostigmine.
After washing galantamine, the effect on 2
1p was fully reversible,
but the depression of a2
1p was not.
Overall, the results indicate that AChE inhibition does not
increase a2, and thus suggest that the increase of a2 induced by
NS9283 at concentrations between 1 and 10M cannot be attrib-
uted to the inhibition of AChE. They further suggest that the
prolongation of the decay of the EPSC by blockade of AChE
requires that more than half of the enzyme activity be inhibited,
in which case concentrations of NS9283 a few times higher than
its Ki for AChE would be needed to mimic the effects of neostig-
mine and galantamine, namely, a prolongation of the decay not
associated with an increased amplitude of a2. This hypothesis was
tested by analyzing the effects of NS9283 at 50 M.
NS9283 50M acts on both the nAChRs and the AChE
When NS9283 was applied at 50 M, it produced effects that
resembled those of NS9293 10M. The comparison of the effects
of the two concentrations showed that, although switching from
10 to 50M further increased 2
1p by a factor 2.1 0.6 (NS9283 10
M, n  10, t(9)  6.5197, p  0.00005 vs control) and by a
factor of 3.67 1.24 for NS9283 50 M (n 9, t(8) 7.7494,
p 0.00003 vs control; t(11.007) 3.3840, p 0.0030, Welch test
to compare the two concentrations), a2
1p was evenly increased by
the two concentrations: by a factor 2.60 0.86 for NS9283 10M
(n 10, t(9)3.9035, p 0.0018 vs control) and by a factor of
2.66  0.94 for NS9283 50 M (n  6; t(9)  34.6549, p 
0.0028 vs control; t(9.89)  0.1203, p  0.45, Welch test to com-
pare the two concentrations). This is illustrated in Figure 5A–C in
an experiment where the two concentrations of NS9283 were
applied in succession and in Figure 5E–F by the bar graphs from
multiple experiments. The fact that increasing the NS9283 con-
centration only affects 2
1p mirrors the effects of neostigmine and
is in agreement with an anti-AChE effect. More generally, the data
support the conclusion that up to 10 M the effects of NS9283 are
mostly due to its binding to the nAChRs and saturate at 10 M,
whereas for this concentration the anti-AChE effect is at its threshold
and only becomes important at higher concentrations.
Our previous experiments on AChE inhibition by neostig-
mine at 0.1 and 1 M (Lamotte d’Incamps et al., 2012) showed
that the prolongation of the EPSCs was associated with the devel-
opment of a steady inward current (a few 10s of pA at60 mV for
neostigmine 1 M) and an increased variance of the holding cur-
rent, which allowed evaluation of an elementary current (1 pA
at 60 mV) close to that induced by ACh applied exogenously.
Similar observations were made by Katz and Miledi (1977) at the
neuromuscular junction when AChE was blocked, and were ex-
plained by the buildup of “ambient” ACh leaking from the nerve
terminal. In contrast, NS9283 at 10 M was reported not to in-
duce any inward current, whether in expression systems in which
no AChE is present (Grupe et al., 2013) or in slices (Timmer-
mann et al., 2012). This suggested that the presence of an inward
current could be a test of the inhibition of AChE.
The effects of NS9283 on the holding current and its variance
were analyzed at concentrations from 1 to 50M. Up to 3M, we
could not detect any increase of either the holding current or its
variance. At 10 M, there was a small increase in the variance of
the holding current in 13 of 23 experiments with a mean value of
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Figure 3. NS9283 is a noncompetitive inhibitor of AChE. NS9283 was applied at concentra-
tions ranging from1 to 9M. TheAChE activity ofmouse recombinantAChEwasmeasuredwith
ATC in the concentration range of 0.1 to 1.0mM. The velocity of hydrolysis of ATC is expressed as
Vnorm defined as v/Vmax (where v is the velocity in a given condition and Vmax is the maximum
velocity measured in the absence of inhibitor). The Kmmeasured in the absence of NS9283was
0.10 0.01mM. NS9283 shows a noncompetitive inhibition profile. The Ki was evaluated (see
Materials and Methods) as 11.2 0.8M (three experiments).
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7.2 5.0 pA 2 (t(22) 3.7189, p 0.0012, one-sample t test), but
the associated inward current was too small to be evaluated on a
background showing some increased leak current. In contrast,
when NS9283 was applied at 50 M, there was an inward current
in all experiments but 1 (out of 8) with a mean value of 22.3 
13.9 pA (t(7)  3.6543, p  0.0081, one-sample t test) and an
increased variance of 28.3 18.5 pA 2 (t(7) 3.5336, p 0.0096,
one-sample t test).
In a parallel analysis with neostigmine, one could detect nei-
ther an inward current nor a change in variance of the holding
current at neostigmine 30 nM. At 50 nM, we observed small changes
of both parameters, which developed in 10s of minutes, like the
changes in the EPSCs (Fig. 4). The changes in holding current were
obscured by small changes of the leak current over these periods, but
in 6 of 8 cells, the changes of variance were more robust and their
average value was 10.7 5.5 pA2 (t(7) 3.3346, p 0.013). These
observations suggest that neostigmine or NS9283 only induce a leak
of ACh when their concentration is3–5 times theKi (i.e., when the
AChE inhibition is nearly complete).
The inhibition of AChE by NS9283 does prolong the EPSCs,
but this effect is not significant for concentrations of NS9283
	10 M, at which NS9283 saturates its binding site on A3B2
nAChRs.
The effects of NS9283 and neostigmine in 2/mice
There is evidence that the nAChRs of RCs in WT mice contain
not only 4 and 2 subunits but also 2 and 4 subunits (Ishii et
al., 2005; Lamotte d’Incamps and Ascher, 2013; Perry et al.,
2015). The effects of NS9283 observed in A3B2 recombinant
42 nAChRs have been looked for in A3B2 assemblies of 22,
24, and 44 nAChRs (Lee et al., 2011; Timmermann et al.,
2012; Wang et al., 2015), and there is agreement on the fact that
the potentiation is present in 22 nAChRs. However, in the case
of 4-containing receptors (hereafter noted 4* nAChRs, resp. 2*
for those containing the 2 subunit), Timmermann et al. (2012)
reported positive effects of NS9283 on both24 and44 nAChRs,
whereas Wang et al. (2015) saw no effect on 24 nAChRs, and Lee
et al. (2011) saw no effect on 44 nAChRs. To try to evaluate the
contribution of4 subunits in the case of the RC, we analyzed2
/
knock-out mice (see Materials and Methods).
In 2
/ mice, the EPSCs were very similar to the WT mice
EPSCs (Lamotte d’Incamps and Ascher, 2013) and similarly af-
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and a2 (Fig. 1). **p	 0.01. ***p	 0.001.
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fected by NS9283 at 10M, although less potently. The amplitude
a2
1p of the slow component of the EPSC increased by a factor of
1.56 0.45 (n 9, t(8)  3.723, p 0.0029), whereas the value
for the WT was 2.60 0.86 (n 10; p 0.0018 vs control; t(13.91)
3.3633, p 0.0024, Welch test to compare the two strains); the
value of 2
1p increased by a factor of 1.13  0.38 (n  9, t(8) 
1.0076, not significant, p 0.17) versus a value of 2.1 0.6 in WT
(n 10, p 0.00005 vs control, t(15.68)4.4748, p 0.00020,
Welch test to compare the two strains). We observed similar
discrepancies between 2
/ and WT mice for a2
5p and 2
5p.
In 2
/ mice, nicotine at 1 M induced a current with an
amplitude comparable with that of the current induced in WT
mice (2
/ 175 119 pA; n 6; WT: 215 93 pA; n 5; t(8.98)
0.62, p  0.55, Welch test). The potentiation by NS9283 10 M
was 1.4  0.8-fold (n  4, t(3)  3.4053, p  0.042, paired t
test). Finally, saz-A at 50 nM, which induced a large current in WT
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Figure 5. NS9283mimics the effects of neostigmine but only at high concentrations. NS9283 at 10M prolongs the decay (2, C) and increases the amplitude (a2,D) of the EPSC. Increasing the
concentration to 50M induces a further slowing of the decay2 but not a further increase of the amplitude of the slow component.A,B, 1p-EPSC (A) and 5p-EPSC (B) in control,with 10MNS9283
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1p (C, open circles), 2
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mice (558  358 pA, n  6, t(5)  3.8115, p  0.012), did not
induce any inward current in 2
/ mice, and NS9283 had no
measurable effect when added on saz-A (n 3). saz-A has been
shown to activate some 4* receptors, but with an EC50 in the 100
nM range (Campling et al., 2013; Jensen et al., 2014). The results
thus suggest that, at concentrations of 	50 nM, the effects of
saz-A in WT mice involve 2* nAChRs, some of which could
associate 2 and 4 subunits.
Zn prolongs sEPSCs
García-Colunga et al. (2001) reported that, on 24 nAChRs ex-
pressed in Xenopus oocytes, Zn potentiated the ACh induced
current without inducing a current by itself. This observation was
later extended to42,44,34, and22 nAChRs by Hsiao et
al. (2001), and Hsiao et al. (2008) showed that, at the single-
channel level, the potentiation resulted from an increased burst
duration, and predicted that Zn should prolong the decay of
synaptic currents mediated by the corresponding receptors. Mo-
roni et al. (2008) and Mazzaferro et al. (2011) then found that, in
42 nAChRs, the Zn potentiation is specific of (4)3(2)2 recep-
tors and due to the binding of Zn at the 4-4 interface. The
maximum potentiation was obtained with a Zn concentration of
100 M. In contrast, at a concentration of 10 M, Zn does not
potentiate (4)3(2)2 receptors but has a selective antagonist ef-
fect on (4)2(2)3 receptors (Moroni et al., 2008).
When Zn was applied at 10 M on the MN-RC synapse (5
experiments), it did not produce a significant change in either the
amplitude or the decay of either the 1p eEPSCs (amplitude Ctrl
189 158 pA, Zn 165 143 pA, n 5, t(4) 2.1482, p 0.098;
w Ctrl 24.1 10.4 ms, Zn 26.3 10.7 ms, n 5, t(4)0.4619,
p  0.67) or the sEPSCs (amplitude Ctrl 14.1  0.2 pA, n  2
experiments, Zn 16.3  4.2 pA, n  3, Mann–Whitney U  2,
p 0.8; w Ctrl 11.8 2.2 ms, n 2, Zn 15.5 3.9 ms, n 3,
Mann–Whitney U  1, p  0.4) (Fig. 6A,B). In contrast, when
Zn 100 M was applied, the eEPSC showed a rapid and strong
reduction, sometimes disappearing completely (Ctrl 301  158
pA, Zn 65.4  54.3 pA, n  7, t(6)  4.9272, p  0.0013). This
effect was likely presynaptic as Zn in the range of 100M is known
to block most Ca channels (Magistretti et al., 2003). On the other
hand, the amplitude of sEPSCs was not modified (Ctrl 15.4 5.4
pA, Zn 15.1 3.1 pA, n 4, t(3) 0.162, p 0.88), while their
decay was slowed: w increased from 12.3 1.7 ms to 21.1 3.9
ms (n 4, t(3)6.1056, p 0.088), and this was mostly due to
a prolongation of the slow time constant, which increased from
27.7 12.6 ms to 45.4 10 ms (n 3, t(2)8.3969, p 0.014;
Fig. 6A). These data are in the direction predicted by Hsiao et al.
(2008) from their analysis of single channels activated by ACh
application. They support the notion that sEPSCs are mostly and
possibly exclusively mediated by A3B2 receptors.
In the reduced eEPSCs, the time constants of decay of the two
components were not significantly changed. The amplitudes of
the fast component and of the slow component were both re-
duced, but this reduction was more marked for the fast compo-
nent (Fig. 6C1; a2/a1 went from 0.14 0.06 in Ctrl up to 0.61
0.41 in 100M Zn, n 7, t(6)3.1214, p 0.010). To examine
whether this difference could be related to the reduction of the
ACh release, we analyzed the effects on the eEPSCs of a reduction
of external Ca from 2 to 1 mM. As in the case of Zn, there was little
change in the decay time constants, but the reduction of the slow
component was of the same order, or larger, than that of the fast
component (Fig. 6C2; a2/a1 went from 0.27 0.12 in Ctrl down to
0.15  0.03 in 1 M Ca, n  7, t(6)  2.2738, p  0.031). This
suggests that, in the case of Zn application, the reduction of the
release masks an actual increase of the relative size of the slow
component, similar to that observed with NS9283. The reduction
of the release may also shorten the decay of the EPSC, which is
partly controlled by spillover (Lamotte d’Incamps et al., 2012)
and mask the increase of the dissociation rate.
The effects of Zn reinforce the conclusion, first derived from
the effects of NS9283, that A3B2 receptors are present on RCs.
However, the prolongation induced by Zn appears smaller than
that induced by NS9283, and does not affect in the same propor-
tions as NS9283 the amplitude and the decay of the slow compo-
nent of the synaptic current. This may be linked to the fact that,
although NS9283 and Zn both bind to the - interface, they do
not seem bind to the same amino acids: Moroni et al. (2008)
concluded that 4 H195 and 4 E224 contribute to the Zn 2 bind-
ing site, whereas for the NS9283 binding site Wang et al. (2015)
gave a crucial role to 4 T126 Olsen et al. (2013) to 4 H116 and
Wang et al. (2017) to 4 Q124.
Discussion
A3B2 receptors mediate both components of the EPSC
The speed of decay of synaptic currents involves many factors,
among which the speed of dissociation of the transmitter from
the receptors, desensitization, and the evolution of the transmit-
ter concentration in and around the cleft (Scimemi and Beato,
2009). In our early study of the decay of MN-RC EPSCs, we
proposed that the two components of the decay could reflect the
presence of two heteromeric nAChRs with different affinities for
ACh: low affinity (LS) receptors from which ACh would dissoci-
ate rapidly, and high affinity (HS) receptors from which ACh
would dissociate slowly (Lamotte d’Incamps et al., 2012). At that
time, LS and HS receptors were, respectively, equated with A3B2
and A2B3 receptors, and we thus assumed that the fast compo-
nent would be mediated by A3B2 nAChRs and the slow one by
A2B3 nAChRs. The discovery that the CRR of A3B2 nAChRs has
both an HS and an LS limb (Harpsøe et al., 2011; Wang and
Lindstrom, 2017) opened the possibility that this single class of
stoichiometric variants could be sufficient to explain the biphasic
EPSC: the fast component would result from the activation of
A3B2 nAChRs by a high concentration of ACh binding to both
- interfaces and to the - interface (LS mode), whereas dur-
ing the slow component, due to the lower ACh concentration,
ACh only binds to - interfaces (HS mode).
This hypothesis is supported by the observation that NS9283
and Zn potentiate the slow components of the EPSCs, in agree-
ment with the report by Grupe et al. (2013) that NS9283 slowed
the decay of the responses to brief pulses of ACh. A similar inter-
pretation can explain the slowing of the sEPSCs by Zn (100 M).
The potentiation of the slow component of the EPSCs also agrees
with the single-channel observations, which showed for nonsatu-
rating concentrations of ACh a marked increase in the frequency
of channel openings both on (4)3(2)2 nAChRs exposed to
NS9283 (Mazzaferro et al., 2017) and on 44 nAChRs exposed
to Zn (Hsiao et al., 2008). The kinetic model of the effects of
NS9283 proposed by Indurthi et al. (2016), which proposes that
NS9283 increases the probability of opening of the channels by
acting on “preactivated states” rather than the closed-open tran-
sition or the single-channel conductance, is in good agreement
with these observations.
The observation that NS9283 does not increase the amplitude
of the early component of the EPSCs (Fig. 1) is in agreement with
the observation of Grupe et al. (2013) showing that NS9283 left
shifts the CRR of ACh but is without effect at saturating concen-
trations of ACh. Both observations are at first sight difficult to
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reconcile with the report by Grupe et al. (2013) that NS9283
increased the peak of the response to brief pulses of 1 mM ACh.
The contradiction can be resolved if the ACh concentration is
saturating at the peak of the early EPSC, but not in the case of a
pulse of ACh applied on HEK cells with a theta glass capillary. The
absence of a prolongation of the early EPSC by NS9283 (Fig. 1) is
puzzling, as one would expect that, when the concentration of
ACh decreases after the peak, NS9283 would potentiate a tail
current. However, the decay of the ACh concentration in the
synaptic cleft may actually be extremely rapid due to the presence
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of AChE (	1 ms, as at the neuromuscular junction) (Magleby
and Stevens, 1972), and the early current may entirely originate
from the receptors in which the - interfaces are fully occupied
by a saturating concentration of ACh (in control conditions) or
by ACh and NS9283 (when NS9283 is present).
Two populations of A3B2 nAChRs?
Within the scheme in which the two components of the EPSCs
correspond to two modes of activation of the A3B2 receptors, we
had previously considered the possibility (Lamotte d’Incamps
and Ascher, 2014) that the dissociation constants of ACh in the
LS and HS modes could be directly related to the two time con-
stants of the decay. This appears unlikely, at least for the HS
mode, as the hypothesis predicts long channel openings (or long
bursts of openings) during the slow component of the EPSCs.
This prediction is not supported by the single channel observa-
tions of Carignano et al. (2016) and Mazzaferro et al. (2017) who
only observed short openings of A3B2 nAChRs, whether these
were exposed to low or high ACh concentrations. In addition, the
fact that the time constants of the slow components of the synap-
tic currents are noticeably smaller for sEPSCs than for eEPSCs,
and smaller for 1p-eEPSCs than for 5p-eEPSCs, suggests that
these time constants do not reflect directly the speed of dissocia-
tion of ACh and are influenced by other parameters, such as the
speed of decay of the ACh concentration in and out of the synap-
tic cleft (Lamotte d’Incamps et al., 2012) and possibly desensiti-
zation. We therefore favor a more complex interpretation of the
biphasic EPSC decay, in which A3B2 nAChRs mediate both com-
ponents but are present both in the subsynaptic region (where
they are exposed to a brief pulse of ACh at high concentration)
and in perisynaptic and extrasynaptic regions where they are ac-
tivated by low concentrations of ACh having escaped hydrolysis
by the synaptic cleft AChE and decaying slowly in the absence of
local AChE (Lamotte d’Incamps et al., 2012; Lamotte d’Incamps
and Ascher, 2014).
Evidence for the presence in RCs of nAChRs other than
(4)2(2)3 nAChRs
The effects of NS9283 and of Zn 100 M demonstrate the pres-
ence of A3B2 nAChRs at the MN-RC synapse. They do not dem-
onstrate that all the potentiated receptors are 2* nAChRs, and
they do not exclude that some of the slow component of the
control EPSC be due to A2B3 nAChRs.
The presence of 4* A3B2 nAChRs is made likely by the fact
that, in 2
/ mice, EPSCs and nicotine-induced currents are
potentiated by NS9283. The relatively large size of the currents
induced by low concentrations of cytisine in WT mice could also
indicate a contribution of 4* nAChRs because, for some of these
receptors, cytisine is a full agonist whereas it is only a very weak
partial agonist on 2* nAChRs (Luetje and Patrick, 1991; Papke
and Heinemann, 1994; Harpsøe et al., 2013).
There is evidence for the presence of both A2B3 and A3B2
nAChRs in the CNS (Marks et al., 1999, 2007; Shafaee et al., 1999;
Gotti et al., 2008; DeDominicis et al., 2017), in variable propor-
tions (Kuryatov et al., 2005). However, the similarity between the
potentiations induced by NS9283 on the responses to the four
agonists tested, as well as the fact that Zn at 10M, which has been
shown to inhibit A2B3 nAChRs without affecting A3B2 nAChRs
(Moroni et al., 2008), had no detectable effect on either the eEPSCs
or the sEPSCs, both suggest that, if present, A2B3 nAChRs are not
abundant and contribute little to the synaptic currents.
Can one use NS9283 to identify A3B2 nAChRs?
NS9283 is a useful tool to identify A3B2 nAChRs in the CNS, as
proposed by the discoverers of the compound. Nevertheless, the
anti-AChE properties of NS9283 could complicate the interpre-
tation of the physiological effects of NS9283. In behavioral exper-
iments, NS9283 has been usually applied orally at doses from 0.1
mg/kg up to 3 mg/kg, which Timmermann et al. (2012) extrapo-
lated to brain concentrations of 0.11–3.3 M. However, some
experiments used much higher concentrations (up to 30 mg/kg)
(Rode et al., 2012) at which effects on AChE could become sig-
nificant. Furthermore, the threshold for a functional effect of the
blockade of AChE may not be the same for all central nicotinic
synapses and may be lowered in pathological conditions. Mice
with reduced AChE activity due to heterozygous AChE are more
sensitive to AChE inhibitors (Mohr et al., 2013), which suggests
that partial inhibition of AChE may have important effects in
conditions in which the cholinergic transmission is chronically
impaired, as in Alzheimer’s disease (Wilkinson et al., 2004).
A3B2 nAChRs in the CNSmaymediate both fast and
slow EPSCs
The CNS EPSCs or EPSPs involving heteromeric nAChRs have
time constants of decay varying from a few 10s of milliseconds
(Nose et al., 1991; Bell et al., 2011; English et al., 2011; Lea˜o et al.,
2012; Sun et al., 2013; Unal et al., 2015) to hundreds of millisec-
onds (Hu et al., 1989; Nose et al., 1991; Bell et al., 2011; Ren et al.,
2011; Arroyo et al., 2012; Bennett et al., 2012; Sun et al., 2013; Hay
et al., 2016). The slow EPSCs were often assumed to be mediated
by A2B3 nAChRs because A3B2 nAChRs were initially character-
ized as low affinity LS receptors. As already noted by Timmer-
mann et al. (2012), the discovery that the CRR of A3B2 nAChRs
has a HS foot opened the possibility that A3B2 nAChRs situated
far from the ACh release site may be activated by low concentra-
tions of ACh and mediate slow synaptic currents. This may be in
particular the case for the slow cortical synaptic currents medi-
ated by heteromeric nAChRs, which are often assumed to be
activated by volume transmission (Descarries et al., 1997; Ben-
nett et al., 2012), and which yet may be carried by (4)3(2)2
receptors (DeDominicis et al., 2017).
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